BioSpace News Archive

Techcon, part of OK International and Dover (NYSE: DOV), and a leader in precision fluid dispensing technologies, announced the launch of its new TS9800 Series Jet Valve Dispensing System, the fastest known dispensing system available.

Sientra, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2021.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2021 and provided updates across the company’s pipeline of novel NMDA receptor modulators.

Ligand Pharmaceuticals Incorporated (Ligand) (NASDAQ: LGND) today announced the signing of a definitive merger agreement with Avista Public Acquisition Corp. II (APAC) (NASDAQ: AHPA), a publicly traded special purpose acquisition company (SPAC), providing for the spin-off of OmniAb, Inc. (OmniAb), Ligand’s antibody discovery business, immediately followed by a merger with a newly formed subsidiary of APAC.

Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright Gene Therapy and Gene Editing Conference, being held virtually on March 30, 2022.

Quest Diagnostics (NYSE: DGX), today announced that it has been granted a contract by the Centers for Disease Control and Prevention (CDC) to perform testing and provide laboratory data analysis to help identify patterns in SARS-COV-2 seroprevalence on a multistate basis.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced the finalization of a strategic partnership with the Australian Federal Government to establish a state-of-the-art, domestic mRNA vaccine manufacturing facility in Australia.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that Philip R. Krause, M.D. has joined its Board of Directors.

DUBAI, United Arab Emirates, According to the latest study by Future Market Insights, the Endoscopic Ultrasound Needles Market is expected to reach nearly US$ 223.5 million by 2025 end.

In the last few years, with the rapid development of the healthcare infrastructure, the global market for active implantable medical devices has been gaining traction.